PPARG and exocrine pancreatic carcinoma: Recently, Motomura et al (2000) reported that activation of PPARγ by troglitazone inhibited cell growth and G1 arrest through the increase of cycline dependent kinase inhibitor p27Kip1 in human pancreatic carcinoma cells.